Guardant Health (GH)

Executive Summary

Guardant Health is a leading precision oncology company specializing in blood-based liquid biopsy tests for cancer screening, treatment selection, and monitoring. Its flagship products, Guardant360 for advanced cancer and Shield for early-stage colorectal cancer screening, have driven revenue growth. Shield received FDA approval in July 2024 for colorectal cancer screening in average-risk adults aged 45 and older, a milestone that is expanding the addressable market. The company continues to invest in expanding its test portfolio, including minimal residual disease (MRD) detection and multi-cancer screening. While Guardant Health faces competition from Exact Sciences and others, its proprietary data platform and broad payer coverage provide competitive advantages. The company is not yet profitable but has shown strong revenue growth, with 2025 revenue expected to exceed $700 million. Key risks include reimbursement challenges, competitive pressures, and the need to achieve operating leverage.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval of Guardant360 for Minimal Residual Disease (MRD) in Non-Small Cell Lung Cancer (NSCLC)70% success
• H2 2027Expansion of Shield Screening to Additional Cancer Types (e.g., Pancreatic, Ovarian)50% success
• Q3 2026Positive Data from the ECLIPSE Study Long-Term Follow-Up for Shield85% success